Publications by authors named "G Crofoot"
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear.
Methods: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF).
Article Synopsis
- The SOLAR study compared the effectiveness of a long-acting injection treatment (CAB + RPV LA) to a daily oral regimen (BIC/FTC/TAF) for HIV over 12 months, showing that the injection was just as effective in managing the virus.
- Out of 670 participants, those who switched to CAB + RPV LA reported significantly higher treatment satisfaction and better mental health outcomes compared to those who continued with BIC/FTC/TAF.
- 90% of participants preferred the long-acting injection, indicating a positive shift in perceptions regarding HIV treatment by reducing psychological challenges associated with daily medication regimens.
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.
Clin Infect Dis
August 2024
Background: Lenacapavir is a long-acting HIV-1 capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR) after 104 weeks in adults with multidrug-resistant HIV-1.
Methods: This ongoing, international, Phase 2/3 trial at 42 sites included 72 adults living with multidrug-resistant HIV-1.
Background: Data characterising the long-term use and safety of emtricitabine plus tenofovir disoproxil fumarate as daily oral pre-exposure prophylaxis (PrEP) are scarce and there are uncertainties regarding the value of routine HIV-1 RNA testing during oral PrEP follow-up.
Methods: The DISCOVER trial was a randomised, controlled, phase 3 trial in which cisgender men and transgender women aged 18 years and older with a high likelihood of acquiring HIV were recruited from 94 clinics in Europe and North America and randomly assigned to receive either emtricitabine plus tenofovir disoproxil fumarate (200/25 mg) tablets daily, with matched placebo tablets, or emtricitabine plus tenofovir alafenamide (200/300 mg) tablets daily, with matched placebo tablets, for at least 96 weeks. After completion of the trial, participants were offered enrolment in this 48-week open-label extension study of emtricitabine plus tenofovir alafenamide.
Article Synopsis
- The study explores a long-acting HIV treatment combining broadly neutralising antibodies (bNAbs) with lenacapavir, aiming for improved patient adherence and viral suppression.
- Conducted at 11 treatment centers in the USA, the phase 1b trial included adults who had maintained viral suppression with oral antiretroviral therapy and were tested for their reaction to the bNAbs.
- Out of 21 participants, no serious adverse events were noted, while some mild reactions occurred, indicating the treatment's potential safety and feasibility for long-term use.